Most of the behavioral effects of cannabis and its active ingredients, the cannabinoids (D 9 THC being the most abundant of these), appear to be mediated by cannabinoid receptors. Endogenous cannabinoids (endocannabinoids) are lipid mediators that activate these same cannabinoid receptors. Elegant work from several laboratories over the past 5 years has established that endocannabinoids, possibly acting as retrograde messengers, mediate several forms of neuronal plasticity. Endocannabinoid-mediated neuronal plasticity is common, apparently occurring at all neurons that express cannabinoid receptors. Thus, it is likely that D 9 THC produces its effects by interacting with endocannabinoidmediated neuronal plasticity, though whether it does so cooperatively or antagonistically remains an open question. In this review we will briefl y discuss the work establishing endocannabinoids as mediators of neuronal plasticity and then present evidence that a major effect of D 9 THC may be to antagonize the actions of endocannabinoids.
INTRODUCTION
A fundamental objective in cannabinoid research is to understand how cannabis and its primary psychoactive component, D 9 THC, produce their characteristic psychoactive effects. Rapid advances in the cannabinoid fi eld over the past 5 years have put us tantalizingly close to this goal. Here we will review those advances as they relate to synaptic physiology. Modern neuroscience asserts that consciousness and alterations in consciousness are likely mediated by neuronal activity and modulation of this activity. As cannabis and D 9 THC produce prominent alterations in mood, emotion, memory, and perception, it is likely these substances are producing their effects by infl uencing neuronal activity. Below, we will present evidence from several recent studies showing that both endogenous and exogenous cannabinoids have profound effects on neuronal activity, particularly synaptic transmission. We will then argue that it is the interactions between endogenous and exogenous cannabinoids that underlie the psychoactivity of cannabis and its constituents.
THE ENDOCANNABINOID SYSTEM
The endocannabinoid system is a ubiquitous neuromodulatory system with wide-ranging actions whose extent and mechanisms are still being elucidated. It comprises cannabinoid receptors, endogenous cannabinoids (endocannabinoids, eCB ' s), and enzymes responsible for their production, transport, and degradation. Of the several cannabinoid receptors identifi ed either pharmacologically or molecularly, this review will focus on CB1 receptors, as they are the most abundant and best characterized. CB1 receptors are G-protein-coupled receptors (GPCRs), preferentially activating G i/o proteins. 1 Their activation leads to inhibition of adenylyl cyclase, inhibition of certain voltage-sensitive calcium channels (predominately, those found presynaptically), activation of inwardly-rectifying potassium channels, and activation of mitogen-activated protein (MAP) kinase. 1 CB1 receptors are abundantly expressed in the nervous system, particularly in " higher " brain regions, including the cortex, amygdala, and hippocampus. 2 Here the highest levels of CB1 cannabinoid receptors are found on the terminals of cholecystokinin (CCK) positive GABAergic interneurons. 3 , 4 Given their location and the signaling pathways they activate, it is predicted that CB1 receptors will suppress neurotransmission and neuronal excitability. Indeed, several studies have shown this to be the case. [5] [6] [7] Given the locations and actions of cannabinoid receptors, one would expect the presence of an endogenous ligand, a prediction that has been borne out. Specifi cally, 2 families of endocannabinoids have been extensively characterized. The fi rst are amides of arachidonic acid (or closely related polyunsaturated fatty acids) and ethanolamide. The amide class of endocannabinoids is typifi ed by arachidonoyl ethanolamide, also known as anandamide. 8 The second family is arachidonic acid esterifi ed to the 2 position of glycerol (2-arachidonoyl glycerol, or 2-AG). 9 The synthetic pathways for both of these endocannabinoids are quite complex, and the interested reader is encouraged to consult one of several excellent reviews on the topic. 1 , 2 The key feature of the synthesis of these endocannabinoids, for the purposes of this review, is that they exist as preformed precursors in the membrane and thus are enzymatically produced, or " made on demand " in response to specifi c signals, such as increases in intracellular calcium or activation of phospholipase C ␤ by G q/11 metabotropic receptors. How (and even if) endocannabinoids move from the extracellular space to the interior of a cell for degradation remains a subject of controversy. 10 , 11 Nonetheless, evidence from several studies suggests that there is an inhibitable process that facilitates bidirectional transport of endocannabinoids across the cell membrane. 12 , 13 Degradation of the 2 classes of endogenous cannabinoids in vivo also occurs by distinct pathways: fatty acid amide hydrolase primarily degrades anandamide and its congeners, while monoacyl glycerol lipase degrades 2-AG and related esters. 14 , 15 There is also evidence for oxygenase metabolites of endocannabinoids as will be discussed in a later section. While these are the 2 best-characterized families of endocannabinoids, ongoing studies suggest that arachidonic acid conjugated to several molecules, such as amino acids, forms bioactive compounds, many of which have activity at cannabinoid receptors. 16 The exact physiological role and metabolic pathways for the synthesis and degradation of these compounds remain to be delineated.
CANNABINOIDS INHIBIT NEUROTRANSMISSION
There is ample evidence for the proposition that cannabinoids inhibit neurotransmitter release and neurotransmission. Sheldon Roth ' s group published one of the earliest studies, predating even the pharmacological characterization of cannabinoid receptors. 17 They found that D 9 THC and related compounds stereospecifi cally suppressed electrically evoked ilieal contractions. Subsequent work from several labs has extended these studies to central nervous system (CNS) neurons and provides a mechanistic basis for attenuation of neurotransmission by CB1 activation. 5 Presumed mechanisms generally invoke inhibition of presynaptic (eg, N-and P/Q-type) calcium channels 18 , 19 but may also involve activation of potassium channels and CB1-mediated direct inhibition of the vesicular release machinery. 6 
CANNABINOIDS AND NEURAL PLASTICITY
Five years ago a fundamental question in the cannabinoid fi eld was how to relate activity-dependent synthesis of endocannabinoids with their demonstrated ability to inhibit neurotransmission. While studying the phenomenon of depolarization-induced suppression of inhibition (DSI), Rachel Wilson, then in Roger Nicoll ' s lab, worked out an answer to this question, thereby offering a remarkable insight into cannabinoid signaling. 20 In DSI, strong depolarization of a postsynaptic neuron produces a signal that diffuses to the presynaptic terminal and transiently attenuates gamma-aminobutyric acid (GABA) release from that terminal. A similar phenomenon has been reported for glutamate release in excitatory neurons and is designated DSE (depolarization induced suppression of excitation). Through a careful series of experiments, Rachel Wilson ' s work identifi ed cannabinoid receptors as being necessary for DSI and suggested that endocannabinoids served as the retrograde messenger. The proposed scheme was that after their production in the postsynaptic cell, endocannabinoids diffused across the synaptic cleft to activate presynaptic CB1 receptors, thereby inhibiting neurotransmitter release. Contemporaneously with this report, studies from both the Regehr and Kano labs revealed that a similar phenomenon involving endocannabinoids and cannabinoid receptors occurred at excitatory synapses in the cerebellum and hippocampus. 21 , 22 Subsequent work from a large number of groups has shown that DSI and DSE are widespread phenomena, occurring at most synapses expressing CB1 receptors. 23 How does depolarization bring about the production of endocannabinoids? Depolarization will open voltage-dependent calcium channels, increasing calcium inside the neuron. Early studies by Daniele Piomelli and his colleagues found that anandamide production was enhanced as intracellular calcium increased. 24 Similarly, 2-AG synthesis is increased by manipulations that increase intracellular calcium. 9 However, more recent studies suggest that release of calcium from intracellular stores during depolarization is necessary for DSI or DSE to occur and that entry of extracellular calcium plays a minor role, at least at certain synapses. 25 , 26 DSE and DSI are quite transitory, suggesting a very active termination process. Endocannabinoids are rapidly hydrolyzed, making degradation a likely mechanism to terminate DSE and DSI. Insight into which endocannabinoids mediate DSI and DSE can be gained by investigating if inhibition of anandamide or 2-AG degradation alters the time course of DSE or DSI. Inhibition of fatty acid amide hydrolase (FAAH) generally does not prolong DSE or DSI 27 ; however, inhibition of either monoacylglycerol (MAG) lipase or cyclooxygenase does, 27 , 28 suggesting a role for these latter 2 enzymes in the degradation of the endocannabinoids involved in DSE and DSI. Of interest, where it has been examined, endocannabinoid uptake does not seem to be involved in terminating DSE or DSI. 26 , 29 , 30 Indeed, it is inhibition of the putative endocannabinoid membrane transporter that appears to inhibit endocannabinoid-mediated plasticity, suggesting that the transporter might be involved in the egress of endocannabinoids from the postsynaptic cell.
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The above discussion has reviewed the " classical " features of DSI and DSE. However, there are several additional aspects of these processes that should be kept in mind. The fi rst is that in the electrophysiological recordings that are used to study DSI and DSE, what is being measured is the release of small neurotransmitters that activate ligand-gated ion channels. Yet in the hippocampus, GABA is co-localized with CCK in CB1-expressing terminals. Thus, activation of CB1 receptors would be expected to decrease the release of both GABA and CCK. Indeed, this seems to be the case. 31 Therefore, models that attempt to explain the effects of DSI and similar phenomena must also take into account the implications of inhibiting the release of neuromodulators such as CCK. For example, CCK acting through its receptors would be expected to enhance neuronal activity. Thus, the balance between increased excitability secondary to decreased GABA release on the one hand and reduced excitability secondary to decreased CCK release on the other will determine the net effect of DSI on neuronal excitability. The second major point is that neurons are not the only cell type in the CNS that make endocannabinoids -glial cells can produce large quantities of 2-AG, anandamide, and related compounds. 32 The relative contribution of neuronally and glially produced endocannabinoids in the CNS remains to be examined. Finally, the above discussion has been framed in the context of presynaptic CB1 receptors. Despite ambiguous anatomical evidence, there is strong functional evidence for somatic CB1 receptors. Activation of these receptors, possibly by opening inwardly rectifying potassium channels, suppresses neuronal fi ring. Thus a relatively localized release of endocannabinoids can have an effect over a considerably greater distance. Examples of a network effect of locally released endocannabinoids have been found in both the cerebellum and cerebral cortex. 33 , 34 In addition to a short-term neuronal plasticity mediated by endocannabinoids released following depolarization, a similar inhibition can be induced by activation of certain G q/11 -linked receptors. This process has been designated metabotropic-induced suppression of excitation (or inhibition) and is abbreviated MSE (or MSI). The receptors most closely linked to MSE and MSI are group I metabotropic receptors (often mGluR5) and muscarinic receptors (M1 and M3). For MSE and MSI, the following proposed sequence of events would lead to 2-AG production: activation of the GPCR stimulates a phospholipase C ␤ , producing IP 3 and diacylglycerol (DAG). The fatty acid at the one position in DAG is then cleaved by a diacylglycerol lipase, producing 2-AG. MSE/MSI are different from DSE/DSI in that the former do not seem to require a rise in intracellular calcium (however, intracellular calcium may increase secondary to IP3 released by phospholipase C during endo cannabinoid synthesis). 35 , 36 The depolarization-and metabotropic-induced processes occur via independent pathways, and thus when both are activated they can be synergistic in their inhibition of neurotransmission. For example, depolarizations or agonist concentrations, which on their own would not produce a detectable endocannabinoid release, may in combination produce substantial endocannabinoid synthesis and inhibition of neurotransmission. 37 Therefore, it has been proposed that activation of phospholipase C and production of endocannabinoids serves as a coincidence detector between neuronal depolarization and activation of metabotropic receptors linked to G q/11 . 37 Endocannabinoids also participate in at least one form of longterm synaptic plasticity, a type of long-term depression (eLTD). eLTD is evident at certain synapses following prolonged low frequency stimulation of excitatory synaptic inputs. 30 , 38 , 39 Here the process appears to involve the following events. Sustained release of glutamate strongly stimulates postsynaptic mGluR5 receptors. This causes synthesis of endocannabinoids that activate presynaptic CB1 receptors, which sets in motion as-yet-unidentifi ed signaling machinery, which ultimately leads to a sustained decrease in the effi ciency of neurotransmitter release, a characteristic of eLTD. Several features of eLTD should be noted. The fi rst is that while activation of presynaptic CB1 receptors is necessary for eLTD induction, it is not necessary for the maintenance of eLTD. 38 Thus, CB1 receptors in eLTD are activating different signaling pathways than those activated in DSI. In DSI/DSE, the prominent effect appears to be inhibition of presynaptic calcium channels, a process that requires the continued presence of endocannabinoids. The second is that the stimulated excitatory pathway is not necessarily the one that shows eLTD. Rather it may be an adjacent pathway. For example, in the hippocampus, prolonged low frequency stimulation of the excitatory Schaffer collaterals leads to LTD of the inhibitory pathway onto the same dendritic shafts. 40 In contrast, in the nucleus accumbens, the glutamatergic fi bers projecting to this nucleus from the prefrontal cortex contain cannabinoid receptors and their low frequency stimulation leads to LTD of this excitatory synaptic connection to the medium spiny neurons of the accumbens. 41 
INTERACTIONS BETWEEN ⌬ 9 THC AND ENDOCANNABINOID SIGNALING
The above experimental evidence coupled with numerous other studies strongly implicates endogenous cannabinoids as mediators of specifi c forms of short-and long-term synaptic plasticity. An interesting and signifi cant question is: " How would smoked cannabis modify endocannabinoid signaling? " Cannabis is a complex mix of chemicals; however, the dominant psychoactive component is D 9 THC. One expectation that could be inferred from the above studies is that D 9 THC might simply substitute for endogenous cannabinoids and activate the same signaling pathways. Despite the attractive simplicity of the above hypothesis, the actual situation is likely to be more complex.
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more complex than initially suspected. The challenge for the next 5 years will be to identify which actions of endocannabinoids occur in what parts of the brain and to integrate these roles into a broader understanding of the CNS. As emerging results from investigating the interactions between D 9 THC and endocannabinoids illustrate, many of these will not be what we expect.
From several studies, 2-AG appears to be the major endocannabinoid mediating both the transient and persistent forms of endocannabinoid-mediated neuronal plasticity. 26 , 28 , 42 However, D 9 THC (and anandamide) has a much lower intrinsic effi cacy than does 2-AG and will show partial agonism depending on receptor and/or effector density. 43 Thus, depending on CB1 density, 2-AG concentration, the particular repertoire of G proteins activated, and the intracellular signaling pathway, D 9 THC might well antagonize endogenous 2-AG action. This is perhaps a radical theory, but it is supported by several lines of evidence, both in vitro and in vivo. From in vitro experiments we know that D 9 THC antagonizes both synthetic and endocannabinoid-mediated inhibition of synaptic transmission as well as DSE and MSE in cultured autaptic neurons 26 , 44 (Straiker and Mackie, unpublished observations, 2005) . The in vivo evidence is that high doses of the CB1 antagonist only modestly attenuate the subjective effects of cannabis intoxication. 45 , 46 This stands in contrast to the situation with opiates, where very low doses of naloxone will readily block the euphoric effects of opiates such as morphine, methadone, or heroin. Thus, D 9 THC may be producing its effects not by indiscriminately mimicking endogenous cannabinoids but by antagonizing at least some of their actions.
Of interest, the interactions between D 9 THC and endogenous cannabinoids become more complex when examining the effect of chronic D 9 THC. Overnight treatment of cultured neurons with D 9 THC or short-term administration of D 9 THC in animals leads to tolerance to the effects of cannabinoids, both on neurotransmission (in cultures or in slices prepared from chronically treated mice) and behavior (in animal models). Thus, even though the acute effects of endocannabinoids are blocked by D 9 THC, chronic treatment with this compound leads to the development of tolerance indistinguishable from that produced by chronic treatment with highly effi cacious cannabinoids. Therefore, it is likely that D 9 THC, despite its low intrinsic effi cacy and inability to inhibit neurotransmission in cultured neurons, is nonetheless capable of activating the CB1 receptor signaling pathways that lead to desensitization. Potential mechanisms for such a D 9 THC-induced desensitization include CB1 receptor internalization, CB1 receptor sequestration, CB1 receptor phosphorylation, or some combination of all 3. [47] [48] [49] [50] [51] 
SUMMARY
Studies over the last 5 years have given us a tremendously increased understanding of the basic mechanisms of endocannabinoid modulation of neuronal signaling. It is clear that endocannabinoids are made in response to neuronal activity and are centrally involved in some forms of both long and short forms of neuronal plasticity. Furthermore, the interactions between D 9 THC and endocannabinoids are
